

ICRP Committee 1 Meeting

October 21-27, 2013 – Abu Dhabi, UAE

Committee 1 (C1) has expanded to 16 members, 7 of whom are new, so detailed introductions, area's of expertise, and membership on other relevant radiation protection committees for all members were presented.

John Boice (guest Main Commission (MC) member) presented a summary of Task Group (TG) 84 *Radiological protection issues arising during and after the Fukushima nuclear reactor accident* for the benefit of the committee.

Ohtsura Niwa and Jolyon Hendry (Co-chairs) presented an update on TG 75 report *Stem cell biology in relation to carcinogenic radiation risk*. Some issues remain and C1 was advised it could expect a revised version by the end of 2013.

Future plans for TG 64 *Cancer risk from alpha emitters* were summarized by the chair Margot Tirmarche. It was decided that this committee would continue to move forward pending joint analysis of Sellafield and Mayak workers.

Since the last C1 meeting, two new TG's under the auspices of C1 were approved by the MC. TG 91: *Radiation Risk Inference at Low-dose and Low-dose Rate Exposure for Radiological Protection Purposes*; and TG 92: *Terminology & Definitions*. It is anticipated both these TG's will meet before the end of 2013.

Various committee members presented updates on activities at RERF, UNSCEAR, MELODI, OPERRA, NCRP, SUBI, and various programs worldwide investigating low dose radiation effects that might impact recommendations on radiation protection. There were also fruitful discussions with C2 on radiation detriment and C3 on inter-individual radiation sensitivity and interactions on a future TG's were recommended.

With the change in C1 composition there was considerable discussion during the Abu Dhabi Symposium regarding these on-going documents and potential new TG's.

Further areas where work may be initiated and where a watch will be kept:

- I. *Individual human sensitivity to ionizing radiations* (with C3)
- II. *Radiation detriment* (with C2)
- III. *Shape of the dose response for cancer*
- IV. *Uncertainties in dosimetry*
- V. *Late effects from particle therapy*
- VI. *RBE for low energy v. high-energy gammas*
- VII. *Radiation weighting factors for tritium*
- VIII. *Radiation risk in relation to chemical risk*
- IX. *Tissue banking, archival tissues, use and value of these resources*
- X. *Trans-generational effects*

The next meeting of C1 will be held in Beijing at a date to be determined in 2014.